Burning Rock Biotech Limited

3.89+0.4000+11.46%Vol 367.25K1Y Perf -84.09%
Aug 12th, 2022 16:00 DELAYED
BID3.83 ASK3.95
Open3.50 Previous Close3.49
Pre-Market- After-Market3.95
 - -  0.06 1.54%
Target Price
9.75 
Analyst Rating
Strong Buy 1.00
Potential %
150.64 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     47.95
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     45.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
10.19 
Earnings Rating
Market Cap409.18M 
Earnings Date
31st Aug 2022
Alpha-0.06 Standard Deviation0.22
Beta-0.62 

Today's Price Range

3.490.00

52W Range

1.7422.83

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
10.83%
1 Month
11.46%
3 Months
17.17%
6 Months
-49.15%
1 Year
-84.09%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNR3.890.400011.46
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
69.80
-165.10
-165.10
-115.30
-97.54
RevenueValueIndustryS&P 500US Markets
65.06M
0.62
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.23-0.39-69.57
Q04 2021--0.38-
Q03 2021-0.19-0.25-31.58
Q02 2021-0.15-0.30-100.00
Q01 2021-0.14-0.25-78.57
Q04 2020-0.16-0.23-43.75
Q03 2020-0.11-0.18-63.64
Q02 2020-0.20-0.38-90.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date31st Aug 2022
Estimated EPS Next Report-0.15
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume367.25K
Shares Outstanding105.19K
Shares Float105.19M
Trades Count2.43K
Dollar Volume1.40M
Avg. Volume457.19K
Avg. Weekly Volume265.44K
Avg. Monthly Volume291.15K
Avg. Quarterly Volume814.98K

Burning Rock Biotech Limited (NASDAQ: BNR) stock closed at 3.89 per share at the end of the most recent trading day (a 11.46% change compared to the prior day closing price) with a volume of 367.25K shares and market capitalization of 409.18M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 753 people. Burning Rock Biotech Limited CEO is Yusheng Han.

The one-year performance of Burning Rock Biotech Limited stock is -84.09%, while year-to-date (YTD) performance is -59.18%. BNR stock has a five-year performance of %. Its 52-week range is between 1.74 and 22.83, which gives BNR stock a 52-week price range ratio of 10.19%

Burning Rock Biotech Limited currently has a PE ratio of -2.60, a price-to-book (PB) ratio of 1.50, a price-to-sale (PS) ratio of 5.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.71%, a ROC of -42.24% and a ROE of -45.32%. The company’s profit margin is -97.54%, its EBITDA margin is -165.10%, and its revenue ttm is $65.06 Million , which makes it $0.62 revenue per share.

Of the last four earnings reports from Burning Rock Biotech Limited, there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Burning Rock Biotech Limited’s next earnings report date is 31st Aug 2022.

The consensus rating of Wall Street analysts for Burning Rock Biotech Limited is Strong Buy (1), with a target price of $9.75, which is +150.64% compared to the current price. The earnings rating for Burning Rock Biotech Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Burning Rock Biotech Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Burning Rock Biotech Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.75, ATR14 : 0.32, CCI20 : 247.22, Chaikin Money Flow : 0.02, MACD : 0.16, Money Flow Index : 91.06, ROC : 17.17, RSI : 51.35, STOCH (14,3) : 88.30, STOCH RSI : 1.00, UO : 62.27, Williams %R : -11.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Burning Rock Biotech Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and LungPlasma. The company has developed various cancer detection products , involving tumor targeting, oncomitant diagnosis of immune drugs, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress and detection of tumor sensitivity.

CEO: Yusheng Han

Telephone: +86 2034037871

Address: No. 7, Luoxuan 4th Road, Guangzhou 510005, , CN

Number of employees: 753

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

48%52%

Bearish Bullish

66%34%


News

Stocktwits